Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
Certified by Founder
Lodge
Sable Bio
start up
United Kingdom
- London
- 06/02/2024
- Pre-Seed
- $1,883,707
Prevent target safety failures with unique data insights and cutting-edge approaches.
Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities.
Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.
- Industry Biotechnology Research
- Website https://sablebio.com/
- LinkedIn https://www.linkedin.com/company/sable-bio/
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)